Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MK-6552 in Narcolepsy Type 1
NCT06179407Phase 1Terminated
- Sponsor
- Merck & Co.
- Start
- Jan 2024
- Primary completion
- Oct 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of MK-6552 in narcolepsy type 1 (NT1) (2 arms), sponsored by Merck & Co. Primary endpoints: Number of Participants Experiencing an Adverse Event, Number of Participants Discontinuing Study Intervention Due to AE and 1 more. Started Jan 2024; status: terminated.
02
Drugs
MK-6552
03
Conditions
narcolepsy type 1 (NT1)
Beyond the preview
Go deeper on NCT06179407.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06179407.